Search clinical trials for: Darapladib 160 mg

Total 13411 results

GlaxoSmithKline

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

Atherosclerosis

United States
GlaxoSmithKline
The TIMI Study Group

Completed

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52)

Acute Coronary Syndrome

United States, France, Netherlands, Ukraine, Germany, Taiwan, Bulgaria, Hungary, Poland, Russian Federation, Argentina, Belgium, Peru, Philippines, Sweden, Thailand, Israel, Spain, Korea, Republic of, Australia, Czechia, Japan, New... and more
Helios Albert-Schweitzer-Klinik Northeim

Completed

Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy (EC-Cap-SC)

Colorectal Polyps | Colorectal Adenomas

Germany, Poland
GlaxoSmithKline

Completed

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

Atherosclerosis

United States
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
HighField Biopharmaceuticals Corporation
Tigermed Consulting Co., Ltd

Recruiting

Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

Solid Tumor, Adult

China
RemeGen Co., Ltd.

Recruiting

A Study of Telitacicept in Lupus Nephritis

Lupus Nephritis

China
Genencell Co. Ltd.

Recruiting

Efficacy and Safety of ES16001 in Patients With COVID-19

COVID-19

Korea, Republic of
Warner Chilcott

Completed

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

Erectile Dysfunction

United States
UCB Celltech
Parexel; Comac Medical; MAC Clinical Research; ARENSIA, Moldova

Completed

Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis

Psoriatic Arthritis

Bulgaria, Moldova, Republic of, United Kingdom
Rigel Pharmaceuticals

No longer available

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Immune Thrombocytopenic Purpura
RemeGen Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Primary Sjogren's Syndrome

China
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Recruiting

Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)

Acute Malaria

Burkina Faso, Gabon, Mozambique, Uganda
Insmed Incorporated

Completed

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Cystic Fibrosis

United States
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
GlaxoSmithKline

Completed

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

Atherosclerosis

United States
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI); GlaxoSmithKline; National...

Completed

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

Endothelial Dysfunction

United States
GlaxoSmithKline

Completed

A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema

Retinopathy, Diabetic

Australia, Netherlands, Italy, Germany, Denmark
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Grünenthal GmbH

Completed

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Acute Pain

France
GlaxoSmithKline

Completed

SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)

Coronary Heart Disease
GlaxoSmithKline

Completed

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

Atherosclerosis

United States
Warner Chilcott

Completed

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Postmenopausal Osteoporosis

United States
GlaxoSmithKline

Completed

Darapladib China PK

Atherosclerosis

China
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
GlaxoSmithKline

Completed

A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

Atherosclerosis

United States
Vifor (International) Inc.
Fortrea

Completed

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease (ViSionSerenity)

Sickle Cell Disease

United States, France, Greece, Lebanon, United Kingdom
GlaxoSmithKline

Completed

Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-

Atherosclerosis

Japan
GlaxoSmithKline

Completed

A Study With Darapladib to Collect Tolerability Information

Atherosclerosis

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie; Friedreich's Ataxia Research Alliance

Active, not recruiting

RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

Friedreich Ataxia

United States, Australia, Austria, Italy, United Kingdom
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
Bayer

Completed

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Neoplasm

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

IGA Nephropathy

United States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
Rigel Pharmaceuticals

Withdrawn

Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

IGA Nephropathy
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Federation Francophone de Cancerologie Digestive

Completed

Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma . (REGOLD)

Colorectal Adenocarcinoma

France
Corcept Therapeutics

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Ferring Pharmaceuticals

Completed

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Prostate Cancer

United States, Netherlands, Hungary, Czech Republic, Germany, Mexico, Romania, Russian Federation, Ukraine, Canada, Puerto Rico, United Kingdom
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

PLATFORM Study of Precision Medicine for Rare Tumors

Rare Tumor
Ain Shams University

Completed

Doubling the Iron Dose to Prevent IDA in Twin Pregnant Women (IDA)

Hematologic Pregnancy Complications

Egypt
Nocion Therapeutics

Completed

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Refractory Chronic Cough

United States
National Institute of Mental Health (NIMH)
Taisho Pharmaceutical Co., Ltd.

Recruiting

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

Depression | Major Depressive Disorder | Treatment-Resistant Depression

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Japan
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
Merck Sharp & Dohme LLC

Completed

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Human Immunodeficiency Virus-1 (HIV-1)
RemeGen Co., Ltd.

Completed

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

China

Search clinical trials for: Darapladib 160 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations